+357 96 030922
info@marketpublishers.com

Psychedelic-Assisted Therapy Market Size, Share, and Analysis, By Product Type (Instruments, Reagents & Consumables, Software & Services), By Application (Clinical Diagnostics, Drug Discovery & Development, Patient Monitoring, Others), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotech Companies, Others), By Region (North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America) and Regional Forecast 2026–2035

https://marketpublishers.com/r/PF557AE5F197EN.html
Date: May 2026
Pages: 468
Price: US$ 4,260.00 (Single User License)
ID: PF557AE5F197EN

Abstracts

Psychedelic-Assisted Therapy Market was valued at USD $1.20 billion in 2026 and is projected to reach USD $10.31 billion by 2035, registering a CAGR of 27.0% across the forecast period. The Psychedelic-Assisted Therapy Market continues to expand as rising cross-industry adoption, expanding regulatory clarity, and growing capital investment across both developed and emerging markets reshape demand across the value chain.

“Instruments is projected to hold the largest share of the Psychedelic-Assisted Therapy Market through 2035.” This segment continues to gain traction owing to strong existing adoption, favorable total cost of ownership, and vendors bundling advisory and integration services around it to lengthen customer relationships within the Psychedelic-Assisted Therapy Market.

“Hospitals & Clinics is likely to remain the leading end-user segment of the Psychedelic-Assisted Therapy Market.” Budget cycles among these buyers are lengthening as procurement teams weigh total cost of ownership more heavily than

+357 96 030922
info@marketpublishers.com

upfront price, reshaping how vendors package and price psychedelic-assisted therapy offerings for 2026-2035.

“Europe is projected to be the fastest-growing region in the psychedelic-assisted therapy market between 2026 and 2035.” Europe outpaces other regions on the back of supportive regulatory mandates, sustainability-linked procurement policies, and a mature industrial buyer base.

Market Segmentation:

By Product Type: Instruments, Reagents & Consumables, Software & Services

By Application: Clinical Diagnostics, Drug Discovery & Development, Patient Monitoring, Others

By End-User: Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotech Companies, Others

By Region: North America, Europe, Asia-Pacific, Middle East & Africa, Latin America

This report on the Psychedelic-Assisted Therapy Market combines primary and secondary research, triangulated using a bottom-up and top-down approach. Secondary research (~55% of data inputs) drew on paid industry databases, company filings, regulatory data, and trade association statistics. Primary research (~45%) consisted of structured expert interviews with senior executives, product managers, and channel partners across the value chain, used to validate assumptions and surface trends not visible in published data.

Primary interviews substantiate the findings: By Company Type – Tier 1 41%, Tier 2 28%, Tier 3 31%; By Designation – C-level 35%, Directors 31%, Others 34%; By Region – North America 26%, Europe 22%, Asia Pacific 34%, Middle East & Africa 10%, South America 8%.

Key Players active in the Psychedelic-Assisted Therapy

+357 96 030922
info@marketpublishers.com

Market:

Pfizer Inc.

Roche Holding AG

Johnson & Johnson

Novartis AG

Medtronic plc

GE HealthCare

Siemens Healthineers

Strategies observed across these players span product innovation, capacity expansion, and partnerships with channel and technology allies to defend share as new entrants emerge.

Research Coverage: The study defines, segments, and forecasts the Psychedelic-Assisted Therapy Market by product type, application, end-user, and region, with qualitative insight into regulatory context, supply-chain dynamics, pricing trends, and competitive positioning.

Key Benefits of Buying the Report: (1) Identify growth pockets aligned with 2026-2035 demand signals across the Psychedelic-Assisted Therapy Market; (2) Understand the drivers and restraints shaping adoption through the forecast period; (3) Size opportunities in underpenetrated segments and geographies; (4) Anticipate execution risks tied to regulatory shifts and procurement-cycle timing.

Market Developments: The period 2026-2035 is characterized by consolidation among established players, rising investment from new entrants targeting adjacent price tiers, and growing buyer preference for vendors offering integrated, service-attached psychedelic-assisted therapy solutions.

Fatpos Global – Why You Should Purchase This Psychedelic-Assisted Therapy Market

+357 96 030922
info@marketpublishers.com

Report: Access decision-grade analytics built on triangulated primary and secondary research; benchmark competitors with comparative scorecards; and translate insights into sales narratives and partnership plays that improve win rates.

+357 96 030922
info@marketpublishers.com

Contents

1. EXECUTIVE SUMMARY

1.1. Market Share Overview
1.2. Business Trends
1.3. Psychedelic-Assisted Therapy Market: Post-Pandemic & Macroeconomic Outlook
1.4. Key Trends
1.5. Segmentation Snapshot

2. RESEARCH METHODOLOGY

2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
  2.5.1. Paid Sources
  2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation

3. MARKET CHARACTERISTICS

3.1. Market Definition
3.2. Psychedelic-Assisted Therapy Market: Regulatory & Policy Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data

4. PSYCHEDELIC-ASSISTED THERAPY MARKET – INDUSTRY INSIGHTS

4.1. Industry Segmentation
4.2. Supply Chain / Value Chain Analysis
4.3. Industry Ecosystem & Channel Analysis
4.4. Innovation & Sustainability

5. MACROECONOMIC INDICATORS

6. RECENT DEVELOPMENTS

+357 96 030922
info@marketpublishers.com

7. MARKET DYNAMICS

7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends

8. RISK ANALYSIS

9. MARKET ANALYSIS

9.1. Porter's Five Forces
9.2. PEST Analysis
  9.2.1. Political
  9.2.2. Economic
  9.2.3. Social
  9.2.4. Technological

10. PSYCHEDELIC-ASSISTED THERAPY MARKET

10.1. Overview
10.2. Historical Analysis (2021-2025)
  10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

11. PSYCHEDELIC-ASSISTED THERAPY MARKET SIZE & FORECAST 2026A-2035F

11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
  11.3.1. By Product Type
    11.3.1.1. Instruments
      11.3.1.1.1. By Value (USD Million) 2026-2035F
      11.3.1.1.2. Market Share (%) 2026-2035F
      11.3.1.1.3. Y-o-Y Growth (%) 2026-2035F
    11.3.1.2. Reagents & Consumables
      11.3.1.2.1. By Value (USD Million) 2026-2035F

+357 96 030922
info@marketpublishers.com

11.3.1.2.2. Market Share (%) 2026-2035F
11.3.1.2.3. Y-o-Y Growth (%) 2026-2035F
11.3.1.3. Software & Services
11.3.1.3.1. By Value (USD Million) 2026-2035F
11.3.1.3.2. Market Share (%) 2026-2035F
11.3.1.3.3. Y-o-Y Growth (%) 2026-2035F
11.3.2. By Application
11.3.2.1. Clinical Diagnostics
11.3.2.1.1. By Value (USD Million) 2026-2035F
11.3.2.1.2. Market Share (%) 2026-2035F
11.3.2.1.3. Y-o-Y Growth (%) 2026-2035F
11.3.2.2. Drug Discovery & Development
11.3.2.2.1. By Value (USD Million) 2026-2035F
11.3.2.2.2. Market Share (%) 2026-2035F
11.3.2.2.3. Y-o-Y Growth (%) 2026-2035F
11.3.2.3. Patient Monitoring
11.3.2.3.1. By Value (USD Million) 2026-2035F
11.3.2.3.2. Market Share (%) 2026-2035F
11.3.2.3.3. Y-o-Y Growth (%) 2026-2035F
11.3.2.4. Others
11.3.2.4.1. By Value (USD Million) 2026-2035F
11.3.2.4.2. Market Share (%) 2026-2035F
11.3.2.4.3. Y-o-Y Growth (%) 2026-2035F
11.3.3. By End-User
11.3.3.1. Hospitals & Clinics
11.3.3.1.1. By Value (USD Million) 2026-2035F
11.3.3.1.2. Market Share (%) 2026-2035F
11.3.3.1.3. Y-o-Y Growth (%) 2026-2035F
11.3.3.2. Diagnostic Laboratories
11.3.3.2.1. By Value (USD Million) 2026-2035F
11.3.3.2.2. Market Share (%) 2026-2035F
11.3.3.2.3. Y-o-Y Growth (%) 2026-2035F
11.3.3.3. Pharmaceutical & Biotech Companies
11.3.3.3.1. By Value (USD Million) 2026-2035F
11.3.3.3.2. Market Share (%) 2026-2035F
11.3.3.3.3. Y-o-Y Growth (%) 2026-2035F
11.3.3.4. Others
11.3.3.4.1. By Value (USD Million) 2026-2035F
11.3.3.4.2. Market Share (%) 2026-2035F

+357 96 030922
info@marketpublishers.com

11.3.3.4.3. Y-o-Y Growth (%) 2026-2035F

12. NORTH AMERICA PSYCHEDELIC-ASSISTED THERAPY MARKET SIZE & FORECAST 2026A-2035F

12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
  12.3.1. By Product Type
  12.3.2. By Application
  12.3.3. By End-User
12.4. Country
  12.4.1. United States
  12.4.2. Canada

13. EUROPE PSYCHEDELIC-ASSISTED THERAPY MARKET SIZE & FORECAST 2026A-2035F

13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
  13.3.1. By Product Type
  13.3.2. By Application
  13.3.3. By End-User
13.4. Country
  13.4.1. Germany
  13.4.2. United Kingdom
  13.4.3. France
  13.4.4. Italy
  13.4.5. Spain
  13.4.6. Rest of Europe (BENELUX, NORDIC, Poland & Turkey)

14. ASIA-PACIFIC PSYCHEDELIC-ASSISTED THERAPY MARKET SIZE & FORECAST 2026A-2035F

14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
  14.3.1. By Product Type

+357 96 030922
info@marketpublishers.com

14.3.2. By Application
14.3.3. By End-User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. Japan
14.4.4. South Korea
14.4.5. Rest of APAC

15. MIDDLE EAST AND AFRICA PSYCHEDELIC-ASSISTED THERAPY MARKET SIZE & FORECAST 2026A-2035F

15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Product Type
15.3.2. By Application
15.3.3. By End-User
15.4. Country
15.4.1. GCC
15.4.2. South Africa
15.4.3. Rest of Middle East and Africa

16. LATIN AMERICA PSYCHEDELIC-ASSISTED THERAPY MARKET SIZE & FORECAST 2026A-2035F

16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Product Type
16.3.2. By Application
16.3.3. By End-User
16.4. Country
16.4.1. Brazil
16.4.2. Mexico
16.4.3. Rest of Latin America

17. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

17.1. Company Market Share, 2025
17.2. Key Player Overview
17.3. Key Stakeholders

18. COMPANY PROFILES

18.1. Pfizer Inc.
  18.1.1. Company Overview
  18.1.2. Financial Overview
  18.1.3. Key Product / Service Analysis
  18.1.4. Company Assessment
    18.1.4.1. Product Portfolio
    18.1.4.2. Key Clients
    18.1.4.3. Market Share
    18.1.4.4. Recent News & Development (Last 3 Yrs.)
    18.1.4.5. Executive Team
18.2. Roche Holding AG
18.3. Johnson & Johnson
18.4. Novartis AG
18.5. Medtronic plc
18.6. GE HealthCare
18.7. Siemens Healthineers
18.8. Abbott Laboratories
18.9. Thermo Fisher Scientific
18.10. Merck & Co.
18.11. Other Prominent Players

19. APPENDIX

20. CONSULTANT RECOMMENDATION

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Psychedelic-Assisted Therapy Market Size, Share, and Analysis, By Product Type (Instruments, Reagents & Consumables, Software & Services), By Application (Clinical Diagnostics, Drug Discovery & Development, Patient Monitoring, Others), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotech Companies, Others), By Region (North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America) and Regional Forecast 2026–2035

Product link: https://marketpublishers.com/r/PF557AE5F197EN.html

Price: US$ 4,260.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/PF557AE5F197EN.html